AJRCCM:补体系统与肺动脉高压,国自然新的研究思路?

2021-09-26 刘少飞 MedSci原创

肺动脉高压(PH)是一种危及生命的心肺疾病,炎症和免疫已成为关键的早期致病因素。尽管肺动脉高压(PAH)的促炎过程是广泛研究的焦点,但其启动机制仍不清楚。

众所周知,尽管肺动脉高压(PAH)的促炎过程是广泛研究的焦点,但其启动机制仍不清楚。该研究测试了补体级联的激活是否在实验性缺氧性肺动脉高压的启动过程中调节促炎和促增殖过程中起关键作用,并可以作为预测人类肺动脉高压预后的生物标志物。另外分别对实验性PH模型和PAH患者的肺组织进行了免疫荧光染色,对缺乏特定补体成分或循环免疫球蛋白的遗传小鼠模型进行了分析,对培养的人肺外膜成纤维细胞进行了分析,并对PAH患者血浆中的一个生物标志物风险小组进行了网络医学分析。结果发现在实验动物模型和人类中,补体级联的肺血管周围特异性激活被认为是PH的关键决定因素。在实验性低氧PH中,促炎症和促增殖反应依赖于补体(替代途径和成分,免疫球蛋白,特别是IgG,是补体级联激活的关键。研究发现CSF2/GM-CSF是主要的补体依赖性炎症介质。此外,利用网络医学对PAH患者血浆中的生物标记物风险小组进行分析,证明补体信号可以作为预测PAH临床结果的一个因素。

该研究由美国学者发现发表于AJRCCM,其:

研究题目:Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension

期刊年卷:Am. J. Respir. Crit. Care Med. 2020 Jan 15;201(2); 

通讯作者:Stenmark, Kurt R
Division of Critical Care Medicine and Cardiovascular Pulmonary Research, Departments of Pediatrics and Medicine

本研究建立了免疫球蛋白驱动的补体激活失调作为调节实验性缺氧性肺动脉高压的促炎和促增殖过程的关键病理生物学机制,并证明补体信号是决定肺动脉高压临床结局的关键因素。

补体系统是先天免疫的重要组成部分。重要的是,可以触发这种多功能的免疫防御途径,使其成为驱动各种炎症性疾病的有效介体。关于补体在PH和PAH发病机理中的作用,尤其是其在低氧信号传导中的调控-“无菌炎症”,或者补体在临床上对PAH的重要性知之甚少。尽管PAH的一些研究集中于循环中的补体激活,但新兴证据表明,对于局部,组织或细胞特异性的补体成分生产和补体级联的激活具有重要作用。补体是通过三个主要的相互联系的途径激活的:经典途径,替代途径和凝集素。在以无菌炎症为特征的疾病中,替代途径受到了特别的关注。传统的观点认为,抗原-抗体免疫复合物激活补体级联仅涉及经典途径,最近有研究表明,凝集素和替代途径可以由抗体或免疫复合物触发,这一观点受到了挑战。在主动脉瘤,类风湿性关节炎和缺血/再灌注的病理生理学中,已证明了替代途径驱动的抗体介导的补体激活的重要作用。重要的是,即使补体激活是通过经典或凝集素途径启动的,也可以通过替代途径扩增环产生下游补体降解片段的90%。

在这项研究中,测试了以下假设:补体级联反应(特别是涉及替代途径)的激活是调节早期以实验性低氧PH为特征的促炎和促增殖过程的关键病理生物学机制。此外,研究试图确定在更严重的PH(啮齿动物缺氧,一氯肾上腺素)的啮齿动物模型和晚期人类PAH中是否存在补体激活的证据。最后,阐明了循环补体成分是否可以作为人类PAH疾病结局的生物标志物。

原文出处:Frid MG. Immunoglobulin-driven Complement Activation Regulates Proinflammatory Remodeling in Pulmonary Hypertension. Am J Respir Crit Care Med. 2020 Jan 15;201(2):224-239. doi: 10.1164/rccm.201903-0591OC. PMID: 31545648; PMCID: PMC6961733.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1925379, encodeId=8ee919253e909, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 02 22:19:26 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036695, encodeId=a467203669564, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Fri Jan 28 16:19:26 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055065, encodeId=f10b1055065dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16f95520163, createdName=ms6000000447078240, createdTime=Sun Sep 26 18:55:52 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055016, encodeId=56941055016eb, content=都直接变成课题新思路了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 15:57:14 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055020, encodeId=797e1055020df, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Sun Sep 26 15:58:57 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1925379, encodeId=8ee919253e909, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 02 22:19:26 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036695, encodeId=a467203669564, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Fri Jan 28 16:19:26 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055065, encodeId=f10b1055065dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16f95520163, createdName=ms6000000447078240, createdTime=Sun Sep 26 18:55:52 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055016, encodeId=56941055016eb, content=都直接变成课题新思路了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 15:57:14 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055020, encodeId=797e1055020df, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Sun Sep 26 15:58:57 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2022-01-28 isabellayj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1925379, encodeId=8ee919253e909, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 02 22:19:26 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036695, encodeId=a467203669564, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Fri Jan 28 16:19:26 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055065, encodeId=f10b1055065dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16f95520163, createdName=ms6000000447078240, createdTime=Sun Sep 26 18:55:52 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055016, encodeId=56941055016eb, content=都直接变成课题新思路了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 15:57:14 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055020, encodeId=797e1055020df, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Sun Sep 26 15:58:57 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-09-26 ms6000000447078240

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1925379, encodeId=8ee919253e909, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 02 22:19:26 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036695, encodeId=a467203669564, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Fri Jan 28 16:19:26 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055065, encodeId=f10b1055065dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16f95520163, createdName=ms6000000447078240, createdTime=Sun Sep 26 18:55:52 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055016, encodeId=56941055016eb, content=都直接变成课题新思路了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 15:57:14 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055020, encodeId=797e1055020df, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Sun Sep 26 15:58:57 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-09-26 病毒猎手

    都直接变成课题新思路了?

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1925379, encodeId=8ee919253e909, content=<a href='/topic/show?id=26d633354c9' target=_blank style='color:#2F92EE;'>#动脉高压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33354, encryptionId=26d633354c9, topicName=动脉高压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Thu Jun 02 22:19:26 CST 2022, time=2022-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036695, encodeId=a467203669564, content=<a href='/topic/show?id=3bde1518863' target=_blank style='color:#2F92EE;'>#RCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15188, encryptionId=3bde1518863, topicName=RCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d784426, createdName=isabellayj, createdTime=Fri Jan 28 16:19:26 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055065, encodeId=f10b1055065dd, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16f95520163, createdName=ms6000000447078240, createdTime=Sun Sep 26 18:55:52 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055016, encodeId=56941055016eb, content=都直接变成课题新思路了?, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Sun Sep 26 15:57:14 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055020, encodeId=797e1055020df, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c7ad5218670, createdName=14775a26m11暂无昵称, createdTime=Sun Sep 26 15:58:57 CST 2021, time=2021-09-26, status=1, ipAttribution=)]
    2021-09-26 14775a26m11暂无昵称

    学习

    0

相关资讯

Cell Host & Microbe:脑损伤的早产新生儿的肠道-微生物-免疫-脑轴发育异常 

最近,研究人员分析了60名极度早产婴儿的肠道微生物群、免疫学和神经生理学发展,这些婴儿接受了包括抗生素和益生菌在内的标准医院护理。

Cell:肿瘤治疗新方向——药物干预RNA剪接可增强肿瘤免疫

药物干预RNA剪接对抗肿瘤免疫的增强作用。

Nat Med:局部输注HER2特异性CAR-T细胞治疗复发性/难治性中枢神经系统肿瘤儿童和年轻患者的临床研究

CAR-T细胞(嵌合抗原受体T细胞)已被证实对包括胶质母细胞瘤在内的造血系统恶性肿瘤具有临床上的疗效,但目前CAR-T细胞治疗策略在儿童中枢神经系统(CNS)肿瘤中的可行性和耐受性仍有待研究。

CELL:如何通过饮食调节肠道微生物,从而提高免疫力?

最近,研究人员确定了两种以微生物群为目标的饮食干预措施,即植物性纤维和发酵食品,是如何影响健康成年人的体内微生物群和免疫系统。

BMC Infect Dis:母体脊灰病毒抗体对婴儿对脊灰病毒疫苗免疫反应的影响

母体小儿麻痹病毒抗体可以为新生儿提供被动免疫,使其在出生后的头几个月免受小儿麻痹病毒感染,但它们也可能损害婴儿对小儿麻痹病毒疫苗的免疫反应。本研究中,研究人员汇总了基于Sabin毒株的脊髓灰质炎灭活疫

Cell Metab:为什么越老越怕冷?免疫细胞来“背锅”。

IL-33会促进致病的ILC2s增殖,这些ILC2s有内在的缺陷,会促进促炎症反应和降低脂肪组织的恢复能力,而移植成年ILC2s则足以保护老年小鼠免受寒冷。